Completed PHASE2 INTERVENTIONAL 2-arm NCT04307329

Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial (MIMOSA)

Sponsor: AstraZeneca

Updated 12 times since 2020 Last updated: Oct 21, 2024 Started: Mar 23, 2021 Primary completion: Jan 19, 2023 Completion: Mar 23, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Breast Cancer, this trial is completed. The trial is conducted by AstraZeneca and has accumulated 12 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

12 versions recorded

Nov 2024 — Present [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Sep 2022 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Apr 2022 — Sep 2022 [monthly]

Recruiting PHASE2

▶ Show 7 earlier versions

May 2021 — Apr 2022 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2021 — May 2021 [monthly]

Not Yet Recruiting PHASE2
Feb 2021 — Apr 2021 [monthly]

Not Yet Recruiting PHASE2
Jan 2021 — Feb 2021 [monthly]

Not Yet Recruiting PHASE2
Oct 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2
Aug 2020 — Oct 2020 [monthly]

Not Yet Recruiting PHASE2
Apr 2020 — Aug 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
The Netherlands Cancer Institute

Data source: The Netherlands Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amsterdam, Netherlands